Venetoclax
T(11;14)
Mayo ClinicSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the T(11;14) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
mln9708 Mayo Clinic | Phase 1 | CC |
DEXAMETHASONE Mayo Clinic | Phase 1 | CC |
Same molecule, other indications
Venetoclax is also rated in:
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →